Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Recommendation of “Hold” by Analysts

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) has earned an average recommendation of “Hold” from the nine brokerages that are presently covering the stock, Marketbeat.com reports. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $10.00.

A number of analysts recently weighed in on the company. HC Wainwright restated a “buy” rating and issued a $20.00 target price on shares of Zentalis Pharmaceuticals in a research report on Friday, November 15th. Oppenheimer restated an “outperform” rating and issued a $20.00 price objective on shares of Zentalis Pharmaceuticals in a report on Monday, September 16th. Guggenheim reduced their target price on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, November 15th. Finally, Wedbush raised shares of Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 price target for the company in a research note on Monday, August 12th.

Institutional Trading of Zentalis Pharmaceuticals

Several large investors have recently modified their holdings of ZNTL. GSA Capital Partners LLP lifted its holdings in Zentalis Pharmaceuticals by 138.5% in the 3rd quarter. GSA Capital Partners LLP now owns 608,585 shares of the company’s stock worth $2,240,000 after buying an additional 353,384 shares during the period. Decheng Capital LLC raised its holdings in shares of Zentalis Pharmaceuticals by 46.2% during the second quarter. Decheng Capital LLC now owns 3,070,442 shares of the company’s stock valued at $12,558,000 after acquiring an additional 970,859 shares in the last quarter. XTX Topco Ltd lifted its stake in Zentalis Pharmaceuticals by 1,581.9% in the second quarter. XTX Topco Ltd now owns 178,465 shares of the company’s stock worth $730,000 after acquiring an additional 167,854 shares during the period. Renaissance Technologies LLC boosted its holdings in Zentalis Pharmaceuticals by 152.6% in the second quarter. Renaissance Technologies LLC now owns 661,682 shares of the company’s stock valued at $2,706,000 after acquiring an additional 399,745 shares in the last quarter. Finally, Primecap Management Co. CA increased its position in Zentalis Pharmaceuticals by 21.6% during the 3rd quarter. Primecap Management Co. CA now owns 1,498,030 shares of the company’s stock valued at $5,513,000 after purchasing an additional 265,690 shares during the period.

Zentalis Pharmaceuticals Stock Performance

Zentalis Pharmaceuticals stock opened at $3.63 on Friday. Zentalis Pharmaceuticals has a fifty-two week low of $2.66 and a fifty-two week high of $18.07. The firm’s fifty day moving average price is $3.39 and its 200-day moving average price is $4.94. The stock has a market cap of $258.69 million, a P/E ratio of -1.46 and a beta of 1.74.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.36. On average, analysts predict that Zentalis Pharmaceuticals will post -2.48 earnings per share for the current year.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.